IP Library Granted Patent US 9,487,751
Granted Patent B2
US 9,487,751 · App. 13/376,039 · Granted Nov 8, 2016

Method to isolate, identify, and use embryonic stem cells directed to forebrain interneuron fate

Inventors: Stewart A. Anderson (New York, NY); Asif Maroof (New York, NY); Lorenz Studer (New York, NY)
Assignees: CORNELL UNIVERSITY; SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
C12N5/0619A61K35/30A61K35/12C12N2500/44C12N2501/115C12N2501/15C12N2501/155C12N2501/41C12N2506/02C12N2506/45C12N2510/00C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,751
App. No.
13/376,039
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed.

Claims (4)

1. An isolated or a purified preparation of human cortical immature interneuron precursor cells, wherein the human cortical immature interneuron precursor cells of the preparation comprise an exogenous recombinant nucleic acid molecule encoding a marker protein or a therapeutic agent, said recombinant nucleic acid molecule operably linked to at least one of a Lhx6 promoter region and a Lhx6 enhancer region.

2. The isolated or the purified preparation of claim 1 , wherein the human cortical immature interneuron precursor cells of the preparation comprise a genomic ally integrated bacterial artificial chromosome.

3. The isolated or the purified preparation of claim 1 , wherein the therapeutic agent is selected from the group consisting of neuropeptide Y, galanin, adenosine, and GABA.

4. The isolated or the purified preparation of claim 1 , wherein said recombinant nucleic acid molecule is genomically integrated into the cells.

Assignments (4)
CONFIRMATORY LICENSE Recorded Apr 12, 2018
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045922/0750 →
CONFIRMATORY LICENSE Recorded Nov 5, 2012
From: CORNELL UNIVERSITY / CORNELL RESEARCH FOUNDATION, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029244/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2012
From: ANDERSON, STEWART A.; MAROOF, ASIF
To: CORNELL UNIVERSITY
Reel/Frame 027543/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2012
From: STUDER, LORENZ
To: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 027543/0454 →
Continuity (2)
Provisional Application 61183417 · Jun 2, 2009
Related Publication 20120148549A1 · Jun 14, 2012